500 results about "Endometrium" patented technology

A first method for ultrasound uterine medical treatment includes obtaining an end effector having an ultrasound medical-treatment transducer assembly, identifying a blood vessel which supplies blood to a portion of the uterus, and medically treating the blood vessel with ultrasound from the transducer assembly to substantially seal the blood vessel to substantially stop the supply of blood from the blood vessel to the portion of the uterus. In one example, shrinkage of a uterine fibroid is accomplished through use of the end effector endoscopically inserted into the uterus. A second method for ultrasound uterine medical treatment includes endoscopically inserting the end effector into the uterus and medically treating the endometrium lining with ultrasound from the transducer assembly to ablate a desired thickness of at least a portion of the endometrium lining to substantially stop abnormal uterine bleeding from the endometrium lining.

A cryoablation system including a cannula having a proximal end, a distal end, and a longitudinal axis, an expandable balloon extending from the distal end of the cannula and fluidly connected to a source of heat transfer fluid by at least one fluid path, a pump for circulating the heat transfer fluid into and out of the balloon, a probe handle coupled to the proximal end of the cannula and in fluidic communication with the balloon through the cannula, and a heat exchanger for varying the temperature of the heat transfer fluid, wherein the heat exchanger is fluidly connected to a secondary refrigerant source. The heat exchanger may be positioned within the probe handle, within the cannula, or at least partially within the balloon. The heat transfer fluid of this cryoablation system preferably has a freezing point lower than about −110° C. and a boiling point greater than about 50° C.

Drospirenone for Hormone Replacement Therapy A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6beta,7beta; 15beta; 16beta-dimethylene-3-oxo-17alpha-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

A cryoablation system for performing endometrial ablation comprising an elongated tubular cannula having a proximal end, a distal end, and a longitudinal axis, an expandable balloon extending from the distal end of the cannula and fluidly connected to a source of heat transfer fluid by at least one fluid path, a pump for circulating the heat transfer fluid into and out of the balloon, a probe handle coupled to the proximal end of the cannula and in fluidic communication with the balloon through the cannula, and a heat exchanger for varying the temperature of the heat transfer fluid, wherein the heat exchanger is fluidly connected to a secondary refrigerant source, and wherein the heat exchanger comprises an outer tubular wall and a plurality of fins extending from the tubular wall toward the interior portion of the heat exchanger.

A foldable brush self-sampling device for collecting of cell specimens from a body cavity, such as cervix, endometrium, rectum, nasal cavity and fauces, for diagnostic purposes, allows a user to collect cell specimens in the privacy of home. The device includes a sheath and a brush bar. The brush bar would fold into the sheath, which is with smaller diameter. The user inserts the sheath into the cavity easily and pushes the brush bar to expose the brush elements. After insertion of the sheath and push of the brush bar, the brush bar is rotated to obtain the specimen from the body cavity and then retracted in order to return the sheath.

Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

The present devices and methods relate generally to medical devices and methods for cutting, resecting, excising and/or evacuating tissue from various regions of a patient's body. In particular, devices and methods for cutting and/or removing various tissues, e.g., polyps or endometrium, from a uterus or uterine space are provided. Devices and methods for cutting and/or removing various tissues from the human body, such as during laparoscopic or thoracoscopic surgery, are also provided.

A method and composition for effecting necrosis of a tissue lining of a mammalian body cavity, particularly a uterine endometrium, by introducing an applicator comprising a hysteroscope housing a first and a second catheter connected to a catheter into the uterus, distending the uterus by introducing CO2 gas under pressure, delivering a silver nitrate paste to the endometrium through the first catheter and allowing the paste to remain a sufficient amount of time to substantially cauterize the entirety of the tissue lining, particularly the endometrium and delivering an aqueous sodium chloride solution to the uterus through the second catheter thereby neutralizing the silver nitrate and rinsing the uterine cavity.

Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.

An apparatus for ablating tissue with the uterine cavity is provided. The apparatus includes an ablation catheter and an expansible member. The expansible member is attached to the ablation catheter and it has a residual volume greater than the volume of the uterine cavity and exhibits residual dimensions greater than the anatomical dimensions of the uterine cavity.

The present invention relates to efflux inhibitor compositions and methods of using these agents for treating conditions where the activity of efflux transporter proteins (e.g., Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-GP)) inhibit effective delivery of a therapeutic agent to a target tissue (e.g., brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeballs, retina, inner ear, placenta, mammary gland, liver, biliary tract, kidney, intestines, lung, adrenal cortex, endometrium, hematopoietic cells, and/or stem cells).

Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.

The invention belongs to the field of the tumor molecule biology, in particular to a diagnosis reagent, a reagent knit and prevention and cure drugs of endometrial carcinoma, which provides a new diagnosis reagent and medicine for the early diagnosis and the prevention of endometrial carcinoma, and also provides a new method for filtering the medicine used for preventing endometrial carcinoma. The diagnosis reagent for endometrial carcinoma of the invention contains a reagent which can test the expressing level of a human cyclophilin A protein or the content of the mRNA of genes of the human cyclophilin A protein. The medicine which can prevent endometrial carcinoma of the invention includes: the expressing carrier of a shPNA molecule which can express the human cyclophilin A, etc. can change the expressing level of the human cyclophilin A protein or the mRNA content of the genes of the human cyclophilin A protein. The diagnosis reagent of the invention can be used for the early diagnosis of endometrial carcinoma, which has a wide application prospect.

The invention belongs to the field of biological medicines, and particularly discloses a mesenchymal stem cell and cytokine preparation having treatment effects on premature ovarian failures and perimenopausal syndromes, and a preparing method for the preparation. The preparation is composed of umbilical cord or placenta mesenchymal stem cells and cytokines, as well as hyaluronate which is used for bearing the umbilical cord or placenta mesenchymal stem cells and cytokines and has the slow-release and anti-inflammatory effects; and the preparation is injected into a part of the endometrium and ovary in a targeted manner to be slowly released and absorbed. The curative effect of repairing the ovary and endometrium can be achieved, functional ovulation can be promoted, the premature ovarian failures can be treated, and the various perimenopausal syndromes can be remitted. Compared with an existing intravenous re-transfusion and intervention path, untoward effects of intravenous transfusion are avoided through the preparation and a using method of the preparation, abdomen and local wounds caused by interventional treatment are avoided, and side effects and hurts caused by treatment to a patient can be effectively prevented, so that the preparation is safer and more effective, is high in practicability and easy to popularize, and has the huge application value.

Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.

A system for treating uterine tissue having a seal assembly configured for positioning in a patient's cervical canal and uterine cavity; an expandable distal balloon portion; an expandable elongate medial balloon portion configured for movement between a first transversely expanded shape for engaging a cervical canal and a second transversely non-expanded shape for trans-cervical insertion; and a fluid source in communication with distal balloon portion and medial balloon portion for expansion of said balloon portions.